232 related articles for article (PubMed ID: 36496155)
1. Targeting lactate metabolism for cancer immunotherapy - a matter of precision.
Heuser C; Renner K; Kreutz M; Gattinoni L
Semin Cancer Biol; 2023 Jan; 88():32-45. PubMed ID: 36496155
[TBL] [Abstract][Full Text] [Related]
2. Manipulating T-cell metabolism to enhance immunotherapy in solid tumor.
Chen C; Wang Z; Ding Y; Qin Y
Front Immunol; 2022; 13():1090429. PubMed ID: 36618408
[TBL] [Abstract][Full Text] [Related]
3. The Immune Consequences of Lactate in the Tumor Microenvironment.
Harmon C; O'Farrelly C; Robinson MW
Adv Exp Med Biol; 2020; 1259():113-124. PubMed ID: 32578174
[TBL] [Abstract][Full Text] [Related]
4. Hurdle or thruster: Glucose metabolism of T cells in anti-tumour immunity.
Zhang S; Zhang X; Yang H; Liang T; Bai X
Biochim Biophys Acta Rev Cancer; 2024 Jan; 1879(1):189022. PubMed ID: 37993001
[TBL] [Abstract][Full Text] [Related]
5. Targeting tumor-associated acidity in cancer immunotherapy.
Lacroix R; Rozeman EA; Kreutz M; Renner K; Blank CU
Cancer Immunol Immunother; 2018 Sep; 67(9):1331-1348. PubMed ID: 29974196
[TBL] [Abstract][Full Text] [Related]
6. Lactate in the tumour microenvironment: From immune modulation to therapy.
Wang ZH; Peng WB; Zhang P; Yang XP; Zhou Q
EBioMedicine; 2021 Nov; 73():103627. PubMed ID: 34656878
[TBL] [Abstract][Full Text] [Related]
7. Lactate from the tumor microenvironment - A key obstacle in NK cell-based immunotherapies.
Jedlička M; Feglarová T; Janstová L; Hortová-Kohoutková M; Frič J
Front Immunol; 2022; 13():932055. PubMed ID: 36330529
[TBL] [Abstract][Full Text] [Related]
8. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
9. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
10. Targeting glycolysis for cancer therapy using drug delivery systems.
Huang Y
J Control Release; 2023 Jan; 353():650-662. PubMed ID: 36493949
[TBL] [Abstract][Full Text] [Related]
11. A novel strategy to fuel cancer immunotherapy: targeting glucose metabolism to remodel the tumor microenvironment.
Liu X; Zhao Y; Wu X; Liu Z; Liu X
Front Oncol; 2022; 12():931104. PubMed ID: 35924168
[TBL] [Abstract][Full Text] [Related]
12. A novel hypoxia- and lactate metabolism-related signature to predict prognosis and immunotherapy responses for breast cancer by integrating machine learning and bioinformatic analyses.
Li J; Qiao H; Wu F; Sun S; Feng C; Li C; Yan W; Lv W; Wu H; Liu M; Chen X; Liu X; Wang W; Cai Y; Zhang Y; Zhou Z; Zhang Y; Zhang S
Front Immunol; 2022; 13():998140. PubMed ID: 36275774
[TBL] [Abstract][Full Text] [Related]
13. Manipulating Metabolic Alterations and their Consequences to Unleash the Potential of Antitumor Immunotherapy.
Zhu X; Zhu L; Wu Y
Curr Protein Pept Sci; 2022; 23(9):585-601. PubMed ID: 35726423
[TBL] [Abstract][Full Text] [Related]
14. Metabolism and senescence in the immune microenvironment of osteosarcoma: focus on new therapeutic strategies.
Ying H; Li ZQ; Li MP; Liu WC
Front Endocrinol (Lausanne); 2023; 14():1217669. PubMed ID: 37497349
[TBL] [Abstract][Full Text] [Related]
15. Tumor microenvironment-associated lactate metabolism regulates the prognosis and precise checkpoint immunotherapy outcomes of patients with lung adenocarcinoma.
Qiu S; Wang Y; Rao H; Que Q; Wu Y; Zhu R; Feng X; Chi J; Lai W; Sun Y; Xiao Q; Shi H; Xiang Y
Eur J Med Res; 2022 Nov; 27(1):256. PubMed ID: 36411477
[TBL] [Abstract][Full Text] [Related]
16. Fundamentals of T Cell Metabolism and Strategies to Enhance Cancer Immunotherapy.
Rangel Rivera GO; Knochelmann HM; Dwyer CJ; Smith AS; Wyatt MM; Rivera-Reyes AM; Thaxton JE; Paulos CM
Front Immunol; 2021; 12():645242. PubMed ID: 33815400
[TBL] [Abstract][Full Text] [Related]
17. Lactate-Lactylation Hands between Metabolic Reprogramming and Immunosuppression.
Chen L; Huang L; Gu Y; Cang W; Sun P; Xiang Y
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233246
[TBL] [Abstract][Full Text] [Related]
18. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T
Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497
[TBL] [Abstract][Full Text] [Related]
19. Directing Hypoxic Tumor Microenvironment and HIF to Illuminate Cancer Immunotherapy's Existing Prospects and Challenges in Drug Targets.
Ray SK; Mukherjee S
Curr Drug Targets; 2022; 23(5):471-485. PubMed ID: 35021970
[TBL] [Abstract][Full Text] [Related]
20. Impact of tumor microenvironment on adoptive T cell transfer activity.
Martín-Otal C; Navarro F; Casares N; Lasarte-Cía A; Sánchez-Moreno I; Hervás-Stubbs S; Lozano T; Lasarte JJ
Int Rev Cell Mol Biol; 2022; 370():1-31. PubMed ID: 35798502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
